{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T17:36:15Z","timestamp":1772991375301,"version":"3.50.1"},"reference-count":117,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,8,1]],"date-time":"2015-08-01T00:00:00Z","timestamp":1438387200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100011011","name":"Junta de Andaluc\u00eda","doi-asserted-by":"crossref","award":["CTS-7940"],"award-info":[{"award-number":["CTS-7940"]}],"id":[{"id":"10.13039\/501100011011","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100003196","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"FEDER","doi-asserted-by":"publisher","award":["PI12\/01511"],"award-info":[{"award-number":["PI12\/01511"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Spanish foundation of Rheumatology"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Immunopharmacology"],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1016\/j.intimp.2015.06.006","type":"journal-article","created":{"date-parts":[[2015,6,15]],"date-time":"2015-06-15T04:01:22Z","timestamp":1434340882000},"page":"200-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Immunotherapy in antiphospholipid syndrome"],"prefix":"10.1016","volume":"27","author":[{"given":"Ch.","family":"Lopez-Pedrera","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Aguirre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Ruiz-Limon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"P\u00e9rez-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Jimenez-Gomez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Barbarroja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.J.","family":"Cuadrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.intimp.2015.06.006_bb0005","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1002\/art.1780400509","article-title":"Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression","volume":"40","author":"Cuadrado","year":"1997","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0010","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1055\/s-0037-1614881","article-title":"Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome","volume":"82","author":"Dobado-Berrios","year":"1999","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0015","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1002\/1529-0131(200111)44:11<2467::AID-ART426>3.0.CO;2-U","article-title":"The role of TF in the antiphospholipid syndrome","volume":"44","author":"Dobado-Berrios","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0020","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/art.21549","article-title":"Antiphospho-lipid antibodies from antiphospholipid syndrome patients induce monocyte expression through the simultaneous activation of both NFkB\/Rel proteins via p38 MAPK pathway, and the MEK1\/ERK pathway","volume":"54","author":"L\u00f3pez-Pedrera","year":"2006","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0025","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1002\/art.20434","article-title":"Intracellular events in platelet activation induced by antiphospholipid antibodies in the presence of low doses of thrombin","volume":"50","author":"Vega-Ostertag","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0030","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/intimm\/dxh166","article-title":"The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2 glycoprotein I antibodies","volume":"16","author":"Bohgaki","year":"2004","journal-title":"Int. Immunol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0035","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1196\/annals.1422.057","article-title":"In vivo effects of an inhibitor of nuclear factor-kappa B on thrombogenic properties of antiphospholipid antibodies","volume":"1108","author":"Montiel-Manzano","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2015.06.006_bb0040","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1055\/s-0037-1613313","article-title":"NFkappa B is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies","volume":"88","author":"Dunoyer-Geindre","year":"2002","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0045","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1002\/art.21009","article-title":"Involvement of p38 MAPK in the upregulation of tissue factor on endothelial cells by antiphospholipid antibodies","volume":"52","author":"Vega-Ostertag","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0050","doi-asserted-by":"crossref","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","article-title":"Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy","volume":"20","author":"Dvorak","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0055","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1055\/s-0037-1614108","article-title":"Systemic endothelial cell markers in primary antiphospholipid syndrome","volume":"84","author":"Williams","year":"2000","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0060","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1111\/j.1538-7836.2006.02193.x","article-title":"Vascular endothelial growth factor expression in monocytes from patients with primary antiphospholipid syndrome","volume":"4","author":"Cuadrado","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0065","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1002\/art.27299","article-title":"Differential expression of protease activated receptors in monocytes from patients with primary antiphospholipid syndrome","volume":"62","author":"L\u00f3pez-Pedrera","year":"2010","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0070","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1002\/art.23756","article-title":"Proteomic analysis in monocytes of antiphospholipid syndrome patients: deregulation of proteins related to the development of thrombosis","volume":"58","author":"L\u00f3pez-Pedrera","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0075","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1136\/ard.54.10.841","article-title":"Differential distribution of annexins-I, -II, -IV, and -VI in synovium","volume":"54","author":"Goulding","year":"1995","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.06.006_bb0080","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1182\/blood.V97.3.777","article-title":"Plasminogen mediated matrix invasion and degradation by macrophages is dependent on surface expression of annexin II","volume":"97","author":"Falcone","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0085","doi-asserted-by":"crossref","first-page":"13932","DOI":"10.1073\/pnas.0606411103","article-title":"Disulfide isomerization switches TF from coagulation to cell signaling","volume":"103","author":"Ahamed","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.intimp.2015.06.006_bb0090","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.bbrc.2004.04.002","article-title":"Protein disulfide isomerase suppresses the transcriptional activity of NFkB","volume":"318","author":"Higuchi","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.intimp.2015.06.006_bb0095","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1161\/01.CIR.99.17.2227","article-title":"Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression","volume":"99","author":"George","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2015.06.006_bb0100","first-page":"37","article-title":"Autoantibodies associated with atherosclerosis","volume":"32","author":"Shoenfeld","year":"2000","journal-title":"Ann. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0105","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1007\/s12016-007-0008-9","article-title":"Systemic antiphospholipid syndrome and atherosclerosis","volume":"32","author":"Jara","year":"2007","journal-title":"Clin. Rev. Allergy Immunol."},{"issue":"4","key":"10.1016\/j.intimp.2015.06.006_bb0110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1191\/0961203303lu339oa","article-title":"Evaluation of clinical and laboratory features of antiphospholipid syndrome: a retrospective study of 637 patients","volume":"12","author":"Solt\u00e9sz","year":"2003","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.intimp.2015.06.006_bb0115","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1093\/rheumatology\/keh581","article-title":"Preclinical vascular disease in systemic lupus erythematosus and primary antiphospholipid syndrome","volume":"44","author":"Jimenez","year":"2005","journal-title":"Rheumatology"},{"issue":"3","key":"10.1016\/j.intimp.2015.06.006_bb0120","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1046\/j.1365-2249.1997.d01-948.x","article-title":"Involvement of beta2-glycoprotein I and anticardiolipin antibodies in oxidatively modified low-density lipoprotein uptake by macrophages","volume":"107","author":"Hasunuma","year":"1997","journal-title":"Clin. Exp. Immunol."},{"issue":"5","key":"10.1016\/j.intimp.2015.06.006_bb0125","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1177\/096120339600500522","article-title":"Antiphospholipid antibodies and atherosclerosis","volume":"5","author":"Vaarala","year":"1996","journal-title":"Lupus"},{"issue":"6","key":"10.1016\/j.intimp.2015.06.006_bb0130","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1191\/0961203304lu1011oa","article-title":"Antiphospholipid antibodies in acute coronary syndrome","volume":"13","author":"Veres","year":"2004","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.intimp.2015.06.006_bb0135","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2009.07.004","article-title":"Patients with antiphospholipid syndrome display endothelial perturbation","volume":"34","author":"Cugno","year":"2010","journal-title":"J. Autoimmun."},{"issue":"4","key":"10.1016\/j.intimp.2015.06.006_bb0140","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1538-7836.2009.03308.x","article-title":"Atherosclerosis in thrombotic primary antiphospholipid syndrome","volume":"7","author":"Ames","year":"2009","journal-title":"J. Thromb. Haemost."},{"issue":"24","key":"10.1016\/j.intimp.2015.06.006_bb0145","doi-asserted-by":"crossref","first-page":"5859","DOI":"10.1182\/blood-2011-12-400986","article-title":"Mitochondrial dysfunction in antiphospholipid syndrome: implications in the pathogenesis of the disease and effects of coenzyme Q(10) treatment","volume":"119","author":"Perez-Sanchez","year":"2012","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2015.06.006_bb0150","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1191\/0961203302lu165oa","article-title":"Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies","volume":"11","author":"Ames","year":"2002","journal-title":"Lupus"},{"issue":"2","key":"10.1016\/j.intimp.2015.06.006_bb0155","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1136\/ard.2004.023952","article-title":"Premature atherosclerosis in primary antiphospholipid syndrome: preliminary data","volume":"64","author":"Ames","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.06.006_bb0160","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1196\/annals.1422.050","article-title":"Subclinical atherosclerosis in primary antiphospholipid syndrome","volume":"1108","author":"Margarita","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"9","key":"10.1016\/j.intimp.2015.06.006_bb0165","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.imbio.2011.04.001","article-title":"Interaction between oxidative stress and chemokines: possible pathogenic role in systemic lupus erythematosus and rheumatoid arthritis","volume":"216","author":"Shah","year":"2011","journal-title":"Immunobiology"},{"issue":"7","key":"10.1016\/j.intimp.2015.06.006_bb0170","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1056\/NEJM199802123380706","article-title":"Chemokines\u2013chemotactic cytokines that mediate inflammation","volume":"338","author":"Luster","year":"1998","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.intimp.2015.06.006_bb0175","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5551\/jat.12.1","article-title":"Role of thrombogenic factors in the development of atherosclerosis","volume":"12","author":"Marutsuka","year":"2005","journal-title":"J. Atheroscler. Thromb."},{"issue":"1","key":"10.1016\/j.intimp.2015.06.006_bb0180","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/08916930903374741","article-title":"Pathogenic mechanisms in systemic lupus erythematosus","volume":"43","author":"Perl","year":"2010","journal-title":"Autoimmunity"},{"issue":"5","key":"10.1016\/j.intimp.2015.06.006_bb0185","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s11926-003-0029-1","article-title":"Oxidative stress in systemic lupus erythematosus and antiphospholipid syndrome: a gateway to atherosclerosis","volume":"5","author":"Alves","year":"2003","journal-title":"Curr. Rheumatol. Rep."},{"issue":"1","key":"10.1016\/j.intimp.2015.06.006_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-2952(95)02072-1","article-title":"The isoprostanes. Current knowledge and directions for future research","volume":"51","author":"Morrow","year":"1996","journal-title":"Biochem. Pharmacol."},{"issue":"10","key":"10.1016\/j.intimp.2015.06.006_bb0195","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood.V90.10.3931","article-title":"Enhanced lipid peroxidation in patients positive for antiphospholipid antibodies","volume":"90","author":"Iuliano","year":"1997","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.intimp.2015.06.006_bb0200","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1001\/jama.2009.1346","article-title":"Vascular abnormalities, paraoxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome","volume":"302","author":"Charakida","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.intimp.2015.06.006_bb0205","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood-2011-01-330639","article-title":"Antiphospholipid antibodies induce translocation of TLR7 and TLR8 to the endosome in human monocytes and plasmacytoid dendritic cells","volume":"118","author":"Prinz","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0210","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1056\/NEJMra1112830","article-title":"The pathogenesis of the Antiphospholipid syndrome","volume":"368","author":"Giannakopoulos","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0215","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1002\/art.30383","article-title":"Novel assays of thrombogenic pathogenicity in the antiphospholipid syndrome based on the detection of molecular oxidative modification of the major autoantigen \u03b22-glycoprotein I","volume":"63","author":"Ioannou","year":"2011","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0220","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1182\/blood-2009-12-260976","article-title":"Beta2-glycoprotein I can exist in 2 conformations: implications for our understanding of the antiphospholipid syndrome","volume":"116","author":"Agar","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0225","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/j.1538-7836.2008.03021.x","article-title":"Platelet activation by dimeric beta2-glycoprotein I requires signalling via both glycoprotein Ibalpha and apolipoprotein E receptor 2\u2032","volume":"6","author":"Urbanus","year":"2008","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0230","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1002\/art.21968","article-title":"Anti-beta2-glycoprotein I antibodies in complex with beta2-glycoprotein I can activate platelets in a dysregulated manner via glycoprotein Ib\u2013IX\u2013V","volume":"54","author":"Shi","year":"2006","journal-title":"Arthritis Rheum."},{"issue":"3","key":"10.1016\/j.intimp.2015.06.006_bb0235","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1182\/blood-2009-03-206367","article-title":"{beta}2 Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome","volume":"115","author":"Sikara","year":"2010","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.intimp.2015.06.006_bb0240","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1182\/blood-2014-02-554980","article-title":"Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS","volume":"124","author":"Proulle","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0245","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1016\/S0140-6736(10)60709-X","article-title":"Antiphospholipid syndrome","volume":"376","author":"Ruiz-Irastorza","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2015.06.006_bb0250","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1002\/art.21157","article-title":"Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia","volume":"52","author":"Pierangeli","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0255","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1038\/nm1121","article-title":"Heparin prevents antiphospho-lipid antibody-induced fetal loss by inhibiting complement activation","volume":"10","author":"Girardi","year":"2004","journal-title":"Nat. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0260","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1055\/s-0028-1082267","article-title":"Antiphospholipid antibodies and the antiphospholipid syndrome: pathogenic mechanisms","volume":"34","author":"Pierangeli","year":"2008","journal-title":"Semin. Thromb. Hemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0265","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1191\/096120301667486047","article-title":"Placentation, antiphospholipid syndrome and pregnancy outcome","volume":"10","author":"Stone","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2015.06.006_bb0270","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1196\/annals.1422.054","article-title":"Pregnancies complicated with antiphospholipid syndrome: the pathogenic mechanism of antiphospholipid antibodies: a review of the literature","volume":"1108","author":"Di Simone","year":"2007","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2015.06.006_bb0275","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0143-4004(97)80040-9","article-title":"Synthesis of beta2 glycoprotein 1 by the human placenta","volume":"18","author":"Chamley","year":"1997","journal-title":"Placenta"},{"key":"10.1016\/j.intimp.2015.06.006_bb0280","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1136\/ard.2004.021444","article-title":"Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro","volume":"64","author":"Di Simone","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.06.006_bb0285","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1111\/j.1600-0897.2009.00717.x","article-title":"Antiphospholipid antibodies induce a pro-inflammatory response in first trimester trophoblast via the TLR4\/MyD88 pathway","volume":"62","author":"Mulla","year":"2009","journal-title":"Am. J. Reprod. Immunol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0290","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.autrev.2014.01.053","article-title":"14th International Congress on Antiphospholipid antibodies task force report on Antiphospholipid syndrome treatment trends","volume":"13","author":"Erkan","year":"2014","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.06.006_bb0295","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0300","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism (and supplementary appendix)","volume":"363","author":"EINSTEIN Investigators","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0305","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"Investigators Hokusai-VTE","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0315","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s11926-010-0141-y","article-title":"Use of hydroxychloroquine to prevent thrombosis in systemic lupus erythematosus and in antiphospholipid antibody-positive patients","volume":"13","author":"Petri","year":"2011","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2015.06.006_bb0320","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1161\/01.CIR.96.12.4380","article-title":"Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice","volume":"96","author":"Edwards","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2015.06.006_bb0325","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1182\/blood-2008-03-144204","article-title":"Hydroxychloroquine directly reduces the binding of antiphospholipid antibody\u2013beta2-glycoprotein I complexes to phospholipid bilayers","volume":"112","author":"Rand","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0330","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2009-04-213520","article-title":"Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug","volume":"115","author":"Rand","year":"2010","journal-title":"Blood"},{"issue":"576","key":"10.1016\/j.intimp.2015.06.006_bb0335","first-page":"e7","article-title":"Hydroxychloroquine reduces binding of antiphospholipid antibodies to syncytiotrophoblasts and restores annexin A5 expression","volume":"205","author":"Wu","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0340","doi-asserted-by":"crossref","first-page":"R155","DOI":"10.1186\/ar3895","article-title":"Hydroxychloroquine is associated with impaired interferon-alpha and tumor necrosis factor-alpha production by plasmacytoid dendritic cells in systemic lupus erythematosus","volume":"14","author":"Sacre","year":"2012","journal-title":"Arthritis Res. Ther."},{"key":"10.1016\/j.intimp.2015.06.006_bb0345","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/aji.12184","article-title":"Effect of hydroxychloroquine on antiphospholipid antibody-induced changes in first trimester trophoblast function","volume":"71","author":"Albert","year":"2014","journal-title":"Am. J. Reprod. Immunol."},{"issue":"10","key":"10.1016\/j.intimp.2015.06.006_bb0350","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1111\/jth.12363","article-title":"Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients","volume":"11","author":"Schmidt-Tanguy","year":"2013","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0355","series-title":"Hydroxychloroquine for the First Thrombosis Prevention in Antiphospholipid Antibody Positive Patients","year":"2013"},{"key":"10.1016\/j.intimp.2015.06.006_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1161\/01.ATV.0000151647.14923.ec","article-title":"Statins and blood coagulation","volume":"25","author":"Undas","year":"2005","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0365","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1160\/TH04-02-0064","article-title":"New nonlipid effects of statins and their clinical relevance in cardiovascular disease","volume":"91","author":"Undas","year":"2004","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0370","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.2165\/00003495-200363170-00005","article-title":"Effects of HMG-CoA reductase inhibitors on coagulation and fibrinolysis processes","volume":"63","author":"Krysiak","year":"2003","journal-title":"Drugs"},{"key":"10.1016\/j.intimp.2015.06.006_bb0375","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1002\/1529-0131(200112)44:12<2870::AID-ART475>3.0.CO;2-Y","article-title":"Statins prevent endothelial cell activation induced by antiphospholipid (anti-beta2-glycoprotein I) antibodies: effect on the proadhesive and proinflammatory phenotype","volume":"44","author":"Meroni","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0380","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1002\/art.11449","article-title":"Inhibition of the thrombogenic and inflammatory properties of antiphospholipid antibodies by fluvastatin in an in vivo animal model","volume":"48","author":"Ferrara","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0385","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1111\/j.1538-7836.2004.00896.x","article-title":"Fluvastatin inhibits up-regulation of tissue factor expression by antiphospholipid anti-bodies on endothelial cells","volume":"2","author":"Ferrara","year":"2004","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0390","first-page":"18","article-title":"Effect of rosuvastatin on VCAM-1 expression by HUVEC exposed to APS serum in an in vitro model","volume":"25","author":"Mart\u00ednez","year":"2007","journal-title":"Clin. Exp. Rheumatol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0395","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/ard.2010.135525","article-title":"Global effects of fluvastatin on the prothrombotic status of patients with antiphospholipid syndrome","volume":"70","author":"L\u00f3pez-Pedrera","year":"2011","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.intimp.2015.06.006_bb0400","first-page":"3453","article-title":"Neutrophil activation by the tissue factor\/factor VIIa\/PAR2 axis mediates foetal death in a mouse model of antiphospholipid syndrome","volume":"118","author":"Redecha","year":"2008","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2015.06.006_bb0405","doi-asserted-by":"crossref","first-page":"4101","DOI":"10.1182\/blood-2008-12-194258","article-title":"Pravastatin prevents miscarriages in mice: role of tissue factor in placental and foetal injury","volume":"113","author":"Redecha","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0410","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1111\/j.1749-6632.2009.04815.x","article-title":"Statins for the treatment of antiphospholipid syndrome?","volume":"1173","author":"Jajoria","year":"2009","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2015.06.006_bb0415","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"20","author":"Ridker","year":"2008","journal-title":"N. Engl. J. Med."},{"issue":"1\u20132","key":"10.1016\/j.intimp.2015.06.006_bb0420","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bbamem.2003.11.012","article-title":"Metabolism and function of coenzyme Q","volume":"1660","author":"Turunen","year":"2004","journal-title":"Biochim. Biophys. Acta"},{"issue":"18","key":"10.1016\/j.intimp.2015.06.006_bb0425","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1161\/CIRCULATIONAHA.109.906610","article-title":"Inhibiting mitochondrial fission protects the heart against ischemia\/ reperfusion injury","volume":"121","author":"Ong","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.intimp.2015.06.006_bb0430","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.thromres.2004.06.019","article-title":"The antiphospholipid syndrome as a model for B cell-induced autoimmune diseases","volume":"114","author":"Youinou","year":"2004","journal-title":"Thromb. Res."},{"key":"10.1016\/j.intimp.2015.06.006_bb0435","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.autrev.2011.12.011","article-title":"B-cell directed therapies in antiphospholipid antibody syndrome\u2014new directions based on murine and human data","volume":"11","author":"Khattri","year":"2012","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.06.006_bb0440","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.23764","article-title":"Prevention of murine antiphospholipid syndrome by BAFF blockade","volume":"58","author":"Kahn","year":"2008","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0445","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11926-009-0074-5","article-title":"Use of rituximab in the antiphospholipid syndrome","volume":"12","author":"Kumar","year":"2010","journal-title":"Curr. Rheumatol. Rep."},{"key":"10.1016\/j.intimp.2015.06.006_bb0450","first-page":"355","article-title":"Rituximab treatment for resistant antiphospholipid syndrome","volume":"33","author":"Rubenstein","year":"2006","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0455","first-page":"4078","article-title":"Rituximab in the Primary Antiphospholipid Syndrome (PAPS)","volume":"52","author":"Tenedios","year":"2005","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0460","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1177\/0961203311400115","article-title":"Treatment-induced downregulation of antiphospholipid antibodies: effect of rituximab alone on clinical and laboratory features of antiphospholipid syndrome","volume":"20","author":"Sciascia","year":"2011","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2015.06.006_bb0465","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s00277-005-0028-6","article-title":"Successful treatment of thrombocytopenia in primary antiphospholipid antibody syndrome with the anti-CD20 antibody rituximab\u2014monitoring of antiphospholipid and anti-GP antibodies: a case report","volume":"85","author":"Trappe","year":"2006","journal-title":"Ann. Hematol."},{"issue":"Suppl. 1","key":"10.1016\/j.intimp.2015.06.006_bb0470","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1007\/s10067-010-1506-3","article-title":"Successful plasma exchange combined with rituximab therapy in aggressive APS-related cutaneous necrosis","volume":"32","author":"Costa","year":"2013","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0475","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1525-1594.2010.01068.x","article-title":"Combination treatment with plasmapheresis and rituximab for recurrent focal segmental glomerulosclerosis after renal transplantation","volume":"35","author":"Tsagalis","year":"2011","journal-title":"Artif. Organs"},{"key":"10.1016\/j.intimp.2015.06.006_bb0480","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/j.autrev.2013.05.004","article-title":"Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group (European Forum on Antiphospholipid Antibodies). Rituximab use in the catastrophic antiphospholipid syndrome: Descriptive analysis of the CAPS registry patients receiving rituximab","volume":"12","author":"Berman","year":"2013","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.intimp.2015.06.006_bb0485","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/art.37759","article-title":"Rituximab in antiphospholipid syndrome (RITAPS) \u2014 a pilot open-label phase II prospective trial for non-criteria manifestations of antiphospholipid antibodies","volume":"65","author":"Erkan","year":"2013","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0490","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1177\/0961203313491023","article-title":"Rituximab therapy for recurrent thromboembolic disease in antiphospholipid syndrome","volume":"22","author":"Bakshi","year":"2013","journal-title":"Lupus"},{"issue":"10","key":"10.1016\/j.intimp.2015.06.006_bb0495","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/j.1365-2362.2012.02697.x","article-title":"Pathophysiology of thrombosis and pregnancy morbidity in the antiphospholipid syndrome","volume":"42","author":"Oku","year":"2012","journal-title":"Eur. J. Clin. Investig."},{"key":"10.1016\/j.intimp.2015.06.006_bb0500","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1172\/JCI200318817","article-title":"Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome","volume":"112","author":"Girardi","year":"2003","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.intimp.2015.06.006_bb0505","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1182\/blood-2007-01-070631","article-title":"Tissue factor: a link between C5a and neutrophil activation in antiphospholipid antibody induced fetal injury","volume":"110","author":"Redecha","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0510","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1196\/annals.1361.083","article-title":"Complement activation: a novel pathogenic mechanism in the antiphospholipid syndrome","volume":"1051","author":"Pierangeli","year":"2005","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.intimp.2015.06.006_bb0515","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1056\/NEJMc0910965","article-title":"Eculizumab and renal transplantation in a patient with CAPS","volume":"362","author":"Lonze","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0520","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/art.34440","article-title":"Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab","volume":"64","author":"Shapira","year":"2012","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.intimp.2015.06.006_bb0525","series-title":"APLA-LACA","article-title":"Discordant aPTT and anti-FXa values in a catastrophic antiphospholipid syndrome patient receiving intravenous unfractionated heparin","author":"Khianey","year":"2013"},{"key":"10.1016\/j.intimp.2015.06.006_bb0530","series-title":"ClinicalTrials.gov Identifier: NCT00198068","author":"Predictors of Pregnancy Outcome in Systemic Lupus Erythematosus (SLE) and Antiphospholipid Syndrome (APS) (PROMISSE) Accession date 05\/01\/2014","year":"2005"},{"key":"10.1016\/j.intimp.2015.06.006_bb0535","first-page":"99","article-title":"Woodward Award: antiphospholipid syndrome revisited: a disorder initiated by inflammation","volume":"118","author":"Salmon","year":"2007","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"3","key":"10.1016\/j.intimp.2015.06.006_bb0540","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/ncprheum1017","article-title":"New approaches for managing antiphospholipid syndrome","volume":"5","author":"Erkan","year":"2009","journal-title":"Nat. Clin. Pract. Rheumatol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0545","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.thromres.2004.06.031","article-title":"Intracellular signaling triggered by antiphospholipid antibodies in platelets and endothelial cells: a pathway to targeted therapies","volume":"114","author":"Pierangeli","year":"2004","journal-title":"Thromb. Res."},{"key":"10.1016\/j.intimp.2015.06.006_bb0550","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S1462399407000506","article-title":"New targeted therapies for treatment of thrombosis in antiphospholipid syndrome","volume":"9","author":"Pierangeli","year":"2007","journal-title":"Expert Rev. Mol. Med."},{"key":"10.1016\/j.intimp.2015.06.006_bb0555","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejcts.2004.12.005","article-title":"The GP IIb\/IIIa inhibitor abciximab (ReoPro) decreases activation and interaction of platelets and leukocytes during in vitro cardiopulmonary bypass simulation","volume":"27","author":"Straub","year":"2005","journal-title":"Eur. J. Cardiothorac. Surg."},{"key":"10.1016\/j.intimp.2015.06.006_bb0560","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/S0140-6736(06)68734-5","article-title":"Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial","volume":"367","author":"ESPRIT Study Group","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.intimp.2015.06.006_bb0565","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMoa0901301","article-title":"Effect of clopidogrel added to aspirin in patients with atrial fibrillation","volume":"360","author":"ACTIVE Investigators","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.intimp.2015.06.006_bb0570","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1182\/blood-2004-01-0145","article-title":"Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep","volume":"104","author":"Zhou","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.intimp.2015.06.006_bb0575","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S1054-3589(10)59009-4","article-title":"Tissue factor in cardiovascular disease pathophysiology and pharmacological intervention","volume":"59","author":"Holy","year":"2010","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.intimp.2015.06.006_bb0580","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1538-7836.2009.03316.x","article-title":"In vivo inhibition of antiphospholipid antibody-induced pathogenicity utilizing the antigenic target peptide domain I of beta2-glycoprotein I: proof of concept","volume":"7","author":"Ioannou","year":"2009","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.intimp.2015.06.006_bb0585","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1191\/0961203306lu2315oa","article-title":"A peptide that mimics the Vth region of beta-2-glycoprotein I reverses antiphospholipid-mediated thrombosis in mice","volume":"15","author":"Ostertag","year":"2006","journal-title":"Lupus"},{"key":"10.1016\/j.intimp.2015.06.006_bb0590","doi-asserted-by":"crossref","first-page":"J209","DOI":"10.1016\/j.jaut.2011.11.009","article-title":"Anti-phospholipid induced murine fetal loss: novel protective effect of a peptide targeting the beta2 glycoprotein I phospholipid-binding site. Implications for human fetal loss","volume":"38","author":"de la Torre","year":"2012","journal-title":"J. Autoimmun."}],"container-title":["International Immunopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915002969?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567576915002969?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,5,13]],"date-time":"2022-05-13T04:00:15Z","timestamp":1652414415000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567576915002969"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":117,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,8]]}},"alternative-id":["S1567576915002969"],"URL":"https:\/\/doi.org\/10.1016\/j.intimp.2015.06.006","relation":{},"ISSN":["1567-5769"],"issn-type":[{"value":"1567-5769","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy in antiphospholipid syndrome","name":"articletitle","label":"Article Title"},{"value":"International Immunopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.intimp.2015.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}